COMPANY

Replimune

FDA-approved therapeutic company Clinical Phase 3

44 open jobs · last seen Oct 23, 2026 · 14 sources

Keywords: oncology cancer advanced melanoma Hepatocellular Carcinoma Merkel Cell Carcinoma Basal Cell Carcinoma Locally Advanced Cutaneous Squamous Cell Carcinoma Metastatic Uveal Melanoma Biliary Tract Cancer Non-Small Cell Lung Cancer Microsatellite Instability-High Non-melanoma Skin Cancer Cutaneous Melanoma Refractory Metastatic Colorectal Cancer pMMR Metastatic Melanoma Squamous Cell Carcinoma of Head and Neck Locally Advanced Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma Advanced Cutaneous Squamous Cell Carcinoma Metastatic Cutaneous Squamous Cell Carcinoma

Profile checked Oct 10, 2026

Since the raise (Nov 26, 2024): 44 of 44 open jobs were first seen after it.

44Open jobs $140.0MRaised (2 yrs)12Trials (company is sponsor)1FDA records (2 yrs)

Hiring

Title	Location (from posting)	Employer posted	First seen
Manager, FP&A	Woburn, Massachusetts, United States	Oct 19, 2026	Oct 20, 2026
Analyst I, Analytical Services	Framingham, Massachusetts, United States	Oct 15, 2026	Oct 16, 2026
Associate Director, Analytical Services	Framingham, Massachusetts, United States	Oct 15, 2026	Oct 16, 2026
Sr. Medical Science Liaison II - New England	Woburn, Massachusetts, United States	Oct 15, 2026	Oct 16, 2026
Quality Control Laboratory Technician	Abingdon, Oxfordshire, United Kingdom	Oct 14, 2026	Oct 8, 2026

See all 44 jobs

Trial and FDA signals

FDA complete response letter Received an FDA complete response letter (BL 125827, letter dated Apr 10, 2026); 46 roles open. FDA BL 125827 (Apr 10, 2026)
Evidence (1 event)
- Apr 10, 2026 · FDA BL 125827
  CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE APRIL 10, 2026 Replimune, Inc. Attention: Kari Jeschke Woburn, MA (street omitted) Dear Kari Jeschke: Please refer to your Biologics License Application (BLA) received (1

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

Oct 8, 2026 Board tracked Radar started tracking this company’s job board (44 open jobs at last check). source ↗
Aug 6, 2026 FDA FDA New drug/biologic (novel): TUDRIQEV (vusolimogene oderparepvec-wtpg) — BLA125827, Aug 6, 2026. Applicant at approval: Replimune, Inc. source ↗
Dec 12, 2025 Trial start —: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 source ↗
Dec 17, 2024 Trial start 2: A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma source ↗
Nov 26, 2024 Raise Follow-on offering: $140M (total, as published), announced Nov 26, 2024. Source: company release on GlobeNewswire. source ↗
Aug 1, 2024 Trial start Phase 2: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC source ↗
Jul 11, 2024 Trial start Phase 3: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] source ↗
Jan 30, 2024 Trial start Phase 2: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN source ↗
Jun 29, 2023 Trial start Phase 2: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC source ↗
Dec 29, 2020 Trial start Phase 1: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours source ↗
May 15, 2020 Trial start Phase 1/Phase 2: Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies source ↗
Oct 17, 2019 Trial start Phase 1: Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors source ↗
Oct 8, 2019 Trial start Phase 2: Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer source ↗
Sep 20, 2017 Trial start Phase 2: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) source ↗

Upcoming milestones

Oct 31, 2026 (ESTIMATED) · Phase 1 · Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors · NCT04336241
Nov 30, 2026 (ESTIMATED) · Phase 1 · Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours · NCT04735978
Dec 1, 2027 (ESTIMATED) · Phase 2 · Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC · NCT05733598
2028-06 (ESTIMATED) · Phase 2 · Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) · NCT03767348
2029-07 (ESTIMATED) · Phase 1/Phase 2 · Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies · NCT04349436
2030-01 (ESTIMATED) · 2 · A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma · NCT06581406
Sep 30, 2030 (ESTIMATED) · Phase 3 · VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] · NCT06264180
2030-12 (ESTIMATED) · · A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 · NCT06887348

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 44

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Manager, FP&A	Woburn, Massachusetts, United States	Oct 19, 2026	Oct 20, 2026	Not stated
Analyst I, Analytical Services	Framingham, Massachusetts, United States	Oct 15, 2026	Oct 16, 2026	Not stated
Associate Director, Analytical Services	Framingham, Massachusetts, United States	Oct 15, 2026	Oct 16, 2026	Not stated
Sr. Medical Science Liaison II - New England	Woburn, Massachusetts, United States	Oct 15, 2026	Oct 16, 2026	Not stated
Quality Control Laboratory Technician	Abingdon, Oxfordshire, United Kingdom	Oct 14, 2026	Oct 8, 2026	Entry
Associate Director, Process Development	Abingdon, Oxfordshire, United Kingdom	Oct 7, 2026	Oct 8, 2026	Senior
Senior Engineer, Technical Operations	Framingham, Massachusetts, United States	Oct 7, 2026	Oct 8, 2026	Senior
Senior Associate, Clinical Supply Chain	Framingham, Massachusetts, United States	Oct 7, 2026	Oct 8, 2026	Mid
Director, Data Analytics and Reporting	Woburn, Massachusetts, United States	Oct 7, 2026	Oct 8, 2026	Senior
Validation Engineer II	Framingham, Massachusetts, United States	Oct 6, 2026	Oct 8, 2026	Mid
Associate Director, Facilities and Engineering	Abingdon, Oxfordshire, United Kingdom	Oct 2, 2026	Oct 8, 2026	Senior
Senior Quality Control Analyst	Abingdon, Oxfordshire, United Kingdom	Oct 1, 2026	Oct 8, 2026	Senior
Quality Control Analyst I	Abingdon, Oxfordshire, United Kingdom	Oct 1, 2026	Oct 8, 2026	Entry
QC Microbiology Technician	Framingham, Massachusetts, United States	Oct 1, 2026	Oct 8, 2026	Mid
Senior Quality Control, Microbiology Analyst	Framingham, Massachusetts, United States	Oct 1, 2026	Oct 8, 2026	Senior
Director, Medical Publications and Scientific Communication	Woburn, Massachusetts, United States	Sep 30, 2026	Oct 8, 2026	Senior
Director, Clinical Scientist	Woburn, Massachusetts, United States	Sep 29, 2026	Oct 8, 2026	Senior
Associate I, PDT	Framingham, Massachusetts, United States	Sep 29, 2026	Oct 8, 2026	Entry
Senior Associate, Quality Systems	Framingham, Massachusetts, United States	Sep 28, 2026	Oct 8, 2026	Mid
Director, IT Business Partner Commercial	Woburn, Massachusetts, United States	Sep 25, 2026	Oct 8, 2026	Senior
Sr. Medical Science Liaison II (New York/New Jersey)	Woburn, Massachusetts, United States	Sep 25, 2026	Oct 8, 2026	Senior
Sr. Manager, Regulatory Operations (Publishing)	Woburn, Massachusetts, United States	Sep 24, 2026	Oct 8, 2026	Senior
Senior Scientist, Drug Product	Framingham, Massachusetts, United States	Sep 24, 2026	Oct 8, 2026	Senior
Pharmacovigilance Scientist	Woburn, Massachusetts, United States	Sep 23, 2026	Oct 8, 2026	Mid
Analyst II, Analytical Development	Abingdon, Oxfordshire, United Kingdom	Sep 21, 2026	Oct 8, 2026	Mid
Analyst II, Analytical Development	Abingdon, Oxfordshire, United Kingdom	Sep 21, 2026	Oct 8, 2026	Mid
Scientist I, Analytical Development	Abingdon, Oxfordshire, United Kingdom	Sep 21, 2026	Oct 8, 2026	Entry
Scientist I, Quality Control	Abingdon, Oxfordshire, United Kingdom	Sep 18, 2026	Oct 8, 2026	Entry
Scientist I, Quality Control	Abingdon, Oxfordshire, United Kingdom	Sep 18, 2026	Oct 8, 2026	Entry
Quality Assurance Officer I	Abingdon, Oxfordshire, United Kingdom	Sep 17, 2026	Oct 8, 2026	Entry
Senior Manager, Clinical Scientist	Woburn, Massachusetts, United States	Sep 16, 2026	Oct 8, 2026	Senior
Director, Qualified Person	Abingdon, Oxfordshire, United Kingdom	Sep 14, 2026	Oct 8, 2026	Senior
Director, Information Technology	Woburn, Massachusetts, United States	Sep 11, 2026	Oct 8, 2026	Senior
Regional Director - MSL East	Woburn, Massachusetts, United States	Sep 10, 2026	Oct 8, 2026	Senior
Director, HR Business Partner	Abingdon, Oxfordshire, United Kingdom	Sep 8, 2026	Oct 8, 2026	Senior
Executive Director, Market Access and Value	Woburn, Massachusetts, United States	Sep 8, 2026	Oct 8, 2026	Executive
Senior Manager, Data Management	Woburn, Massachusetts, United States	Sep 3, 2026	Oct 8, 2026	Senior
Operational Excellence Lead I (PharmD)	Woburn, Massachusetts, United States	Aug 28, 2026	Oct 8, 2026	Senior
Sr. Scientist, Process Development & Technology	Framingham, Massachusetts, United States	Aug 26, 2026	Oct 8, 2026	Senior
Sr. Director, Clinical Scientist	Woburn, Massachusetts, United States	Aug 26, 2026	Oct 8, 2026	Senior
Sr. Director, Patient Support Services	Woburn, Massachusetts, United States	Aug 19, 2026	Oct 8, 2026	Senior
Senior Director, Trade & Distribution	Woburn, Massachusetts, United States	Aug 19, 2026	Oct 8, 2026	Senior
Medical Director, Global Drug Safety	Woburn, Massachusetts, United States	Aug 6, 2026	Oct 8, 2026	Senior
Process and Equipment Engineer II	Framingham, Massachusetts, United States	Jul 20, 2026	Oct 8, 2026	Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $140.0M. Last 2 years.

Nov 26, 2024 Follow-on offering: $140M (total, as published), announced Nov 26, 2024. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 12

Record	Title	Phase	Status	Start	Primary completion
NCT06264180	VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]	Phase 3	Recruiting	Jul 11, 2024	Sep 30, 2030 (estimated)
NCT04349436	Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies	Phase 1/Phase 2	Active, not recruiting	May 15, 2020	2029-07 (estimated)
NCT06581406	A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma	2	Recruiting	Dec 17, 2024	2030-01 (estimated)
NCT05733598	Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC	Phase 2	Recruiting	Aug 1, 2024	Dec 1, 2027 (estimated)
NCT04336241	Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors	Phase 1	Active, not recruiting	Oct 17, 2019	Oct 31, 2026 (estimated)
NCT04735978	Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours	Phase 1	Active, not recruiting	Dec 29, 2020	Nov 30, 2026 (estimated)
NCT03767348	Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)	Phase 2	Active, not recruiting	Sep 20, 2017	2028-06 (estimated)
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Phase 2	Terminated	Jun 29, 2023	Aug 18, 2025 (actual)
NCT06887348	A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3	Not listed	Recruiting	Dec 12, 2025	2030-12 (estimated)
NCT06590480	An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma	Not listed	No longer available	Not listed	Not listed
NCT05743270	Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Phase 2	Withdrawn	Jan 30, 2024	Mar 1, 2026 (estimated)
NCT04050436	Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer	Phase 2	Active, not recruiting	Oct 8, 2019	2025-09 (estimated)

FDA records (last 2 years)

Aug 6, 2026 FDA New drug/biologic (novel): TUDRIQEV (vusolimogene oderparepvec-wtpg) — BLA125827, Aug 6, 2026. Applicant at approval: Replimune, Inc. source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗
InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗

Connect

See your connections at Replimune on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12